Split congressional control will result in more drug pricing talk, but don’t expect much action.
The price isn’t the real price, even in overseas markets. And if the US government is serious about drug price reductions, should it return to the idea of direct…
Pipeline projects are forecast to contribute a substantial proportion of future sales at Abbvie and Lilly, though the same cannot be said for all big drug developers.
Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…
Big pharma’s freezes have stopped drug price inflation in its tracks, but the temptation to make more hikes could return post-election.
As Anaptysbio pushes forward with its new biological, the cost watchdog Icer questions the prices of products from Glaxosmithkline, Astrazeneca and Teva.
The topline result from Amarin’s Reduce-It trial has smashed expectations, delighting shareholders and framing Vascepa as a potentially practice-changing product.
Fibrogen’s roxadustat has its first European win from the Alps trial, but the most important event is still to come.
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.